DISCOVER SANOFI
FACTSHEET
A GLOBAL HEALTHCARE LEADER
FOCUSED ON PATIENT NEEDS
MAY 2015
KEY FIGURES 1
A STRATEGY
BASED ON FOUR PILLARS
2014 NET SALES
e33,770 M
DEVELOP A GLOBAL HEALTHCARE LEADER
WITH SYNERGISTIC PLATFORMS
Evolution 2013/2014
+4.9%
• Sanofi holds strong positions in its business areas
•N
°1 in Emerging Markets
BRINGING INNOVATIVE PRODUCTS TO MARKET
• 18 new launches are expected between 2014
and 2020.
• 6 launches of new products are underway or imminent
in 2015.
SEIZING VALUE ENHANCING GROWTH OPPORTUNITIES
•W
e have established productive R&D collaborations
with Regeneron and Alnylam.
2014 NET SALES
BY REGION
Rest of
the world 3
$3,219 M
9.5%
Emerging
Markets 2
$11,347 M
33.6%
Western
Europe
$7,865 M
23.3%
United States
$11,339 M
33.6%
2014 BUSINESS EARNINGS
PER SHARE
e5.20
ADAPTING OUR STRUCTURE
FOR FUTURE OPPORTUNITIES AND CHALLENGES
Evolution 2013/2014
+7.3%
• With operations in over 100 countries, we have over
110,000 people committed to respond to global
health needs.
DIVIDEND PER SHARE ($)
2.50
1 - Unless otherwise indicated, all growth rates are expressed at constant exchange rates (CER). On a reported
basis, net sales were up 2.5% and Business EPS increased 3.0% between 2013 and 2014. For further
information on reported growth rates and the definition of Business EPS, please consult the press release
issued on February 5, 2015.
2 - World excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta,
Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway,
Iceland, Denmark), Japan, Australia, and New Zealand.
3 - Row: Japan, Canada, Australia, and New Zealand.
2010
2.65 2.77
2.80
2.85
2011
2013
2014
2012
RÉSULTATS
2014 NET SALES
BY BUSINESS AREAS
% of Sales
PHARMACEUTICALS
€27,720M82.1%
Established Rx Brands
€7,273M
€3,337M
€2,604M
€1,805M
€1,401M
€11,300M
VACCINES €3,974M11.8%
ANIMAL HEALTH
€2,076M6.1%
Diabetes Consumer Healthcare
Genzyme 1
Generics
Oncology 1 - Genzyme includes Rare Diseases and Multiple Sclerosis franchises.
2
SANOFI - FACTSHEET - MAY 2015
21.5%
9.9%
7.7%
5.3%
4.2%
33.5%
RESULTS
SOLID FINANCIAL PERFORMANCE
IN FIRST QUARTER 2015
“Sanofi had a good start to 2015. Our businesses provide
a solid foundation for our new-product cycle. Sanofi’s recent
launches along with the ongoing regulator y reviews and
planned submissions before year-end will drive future growth.
At this important time for the company, my primary focus
will be on maximizing the value of this innovative product
portfolio and further establishing Sanofi as a leading biopharmaceutical company.”
Olivier Brandicourt
Sanofi Chief Executive Officer
NEW PRODUCT LAUNCHES AND PROGRESS IN R&D
• Toujeo®, new long-acting basal insulin was launched in the U.S.
and approved in EU
• Cerdelga®, oral therapy for adult Gaucher disease type 1
patients: approved in Europe and in Japan
• Sales of Lemtrada®, treatment for patients with relapsing
forms of multiple sclerosis, benefited from market introduction
in the U.S.
•D
engue vaccine: rolling submission initiated in six endemic
countries in Asia and Latin America
•D
upilumab: Phase III study initiated in patients with moderateto-severe asthma
FIRST QUARTER 2015
GROUP NET SALES 1
e8,810M
+12.3%
(+2.4%)
EMERGING MARKETS
NET SALES 1 e2,859M
+13.7%
(+7.3%)
BUSINESS NET INCOME 1 e1,726M
+11.6%
(+1.6%)
BUSINESS EPS 1 e1.32
1 - Growth rates are expressed on a reported basis. Growth rates in brackets are expressed at constant exchange
rates (CER).
For definitions of financial indicators, please consult the press release issued on April 30, 2015.
+12.8%
(+2.6%)
SANOFI - FACTSHEET - MAY 2015
3
KEY PRODUCTS
IN THE U.S.*
THE SANOFI SHARE
DIABETES
SANOFI SHARE DETAILS
EURONEXT PARIS, COMPARTMENT A
CANCER
• Mnemonic: SAN
• ISIN code: FR 0000120578
NEW YORK STOCK EXCHANGE
RARE DISEASES
AND MULTIPLE SCLEROSIS
• L isted in the form of American Depository Shares (ADS)
• T rading symbol: SNY
•C
USIP number: 80105N105000
KEY FIGURES
2012
2013
2014
Closing share price at December 31
€71.39
€77.12
€75.66
Highest share price
€72.38
€87.03
€89.95
Lowest share price
€53.20
€65.91
€68.29
€94,688M €102,123M
€99,823M
Market capitalization at December 31
This factsheet contains projections and other forward-looking statements that are not historical facts. Although
the management of Sanofi believes that these projections and forward-looking statements, and their underlying
assumptions, are reasonable as of the date of this factsheet, investors are cautioned that such projections,
assumptions, intentions and forward-looking statements are subject to various risks and uncertainties (many
of which are difficult to predict and generally beyond the control of Sanofi) that could cause actual results and
developments to differ materially from those expressed or implied. These risks and uncertainties include those
discussed elsewhere in this factsheet, as well as in the filings of Sanofi with the U.S. Securities and Exchange
Commission (SEC) and the French Autorité des marchés financiers (AMF), notably under the caption “Risk Factors”
in the company’s annual report on Form 20-F. Other than as required by applicable law, Sanofi does not undertake
any obligation to update any statement that is not a historical fact.
Design and production : SEITOSEI – Photos: © OJO Images/Getty Images, © Randy Monceaux.
•S
anofi U.S. Investor Relations
55 Corporate Drive
Bridgewater, NJ 08807
• T el: 888-516-3002 (toll free)
• [email protected]
•w
ww.sanofi.com/shareholders
•M
obile app: SANOFI IR
(available on the App Store and Google Play)
VACCINES
CONSUMER HEALTHCARE
ANIMAL HEALTH
* For prescribing information, warnings and other
information on these and other products available
in the U.S., please refer to our website: www.sanofi.us